Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial
NCT02440958
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG:
modified FOLFIRINOX regimen
Sponsor
Yonsei University